GlassScriptPhysician profile
Eric S Rosen
NPI 1437390382
$43,159.18
in general payments reported to CMS, 2019-2025
55 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $861 · 2021: $1,465 · 2022: $4,921 · 2023: $2,239 · 2024: $16K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $7,652 · Travel and Lodging: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,575.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,550.00 |
| Food and Beverage | $7,651.61 |
| Travel and Lodging | $1,532.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $30,434.82 | 2019-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Cardiovascular Systems INC. | $3,241.67 | 2019-2023 | Diamondback Coronary |
| Janssen Pharmaceuticals, INC | $885.19 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $810.30 | 2019-2025 | Farxiga, Wainua |
| Amgen INC. | $731.65 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $662.49 | 2022-2025 | |
| Boston Scientific Corporation | $589.15 | 2020-2025 | Rotapro, Watchman Flx, Varithena Administration Pack |
| Abbott Laboratories | $573.09 | 2020-2025 | Aveir, Perclose Prostyle, Perclose Proglide |
| Abiomed | $558.74 | 2022-2025 | Impella |
| Bard Peripheral Vascular, INC. | $457.82 | 2019-2025 | Venclose Maven Catheter, Venovo, Rotarexs 6 F X 135 Cm |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $406.83 | 2019-2025 | Lifevest |
| Medtronic, INC. | $325.11 | 2021-2025 | Closurerfs, Venaseal, Closurefast |
| Alnylam Pharmaceuticals INC. | $324.99 | 2020-2025 | Onpattro |
| Pfizer INC. | $268.67 | 2019-2025 | |
| Cvrx, INC. | $263.49 | 2023-2025 | Barostim Neo System |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.